Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)
- Funder
- National Institutes of Health
- Award amount
- Not specified
- Deadline
- June 16, 2028
- Eligible countries
- United States
Summary
This notice of funding opportunity (NOFO) uses a R61/R33 Phased Innovation Award activity code to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying substance use disorders (SUD), including fundamental circuitry and behavior relevant to substance use. For projects not requiring a phased research approach, applicants are encouraged to apply under a different funding activity code (e.g., PA-25-305 "Research Project Grant (Parent R01 Clinical Trial Required)" or its subsequent reissue).
Summary as listed on Grants.gov (opportunity 361518). Always read the full announcement for eligibility, limits and how to apply.
Read the full announcement on Grants.gov →What National Institutes of Health reviewers look for
- Importance of the research (significance and innovation), scored 1–9.
- Rigor and feasibility of the approach, scored 1–9. Preliminary data and alternative strategies carry much of this.
- Expertise and resources, rated sufficient or not, without a score.
- Overall impact: the likelihood the project will have a sustained, powerful influence on its field.
Read our guide: what funded applications do →
See how this call matches your research
Build a free research profile and GrantMatch scores every open call against your work, tracks your deadlines and reminds you before they pass.
Get matched free